✉news BusinessRetail first seen 14 h ago, last 3 h ago, peak #27
DFTX Stock Rallies On Positive Anxiety Trial Results
Original: DFTX Stock Rallies As Psychedelic Drug Delivers Positive Anxiety Trial Results — Retail Says DT120 Could ‘Disrupt The Market’
Drug Development & Technology company DFTX saw its shares rally after its psychedelic drug candidate DT120 delivered positive results in an anxiety trial. Retail investors are arguing the drug could disrupt the market for anxiety treatments, fueling optimism about the company's prospects in the growing psychedelic medicine sector.
Why now: Positive clinical trial data for DT120 drove the stock higher and excited retail investors about the drug's commercial potential.
Rank over time, top of the chart is #1. 2 snapshots from 4 h ago to 3 h ago.
Evidence
API: https://socialmediatrends-api.osmike.com/v1/trends/985947